Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ricardo García-Fumero, Cristina Fernández-López, Miguel Ángel Calleja-Hernández & José Expósito-Hernández. (2021) Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1. Acta Oncologica 60:9, pages 1225-1232.
Read now
Read now
Urska Janzic, Lea Knez, Andrej Janzic & Tanja Cufer. (2019) Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 717-723.
Read now
Read now
Articles from other publishers (16)
T. Hofmarcher, P. Szilagyiova, A. Gustafsson, T. Dolezal, P. Rutkowski, C. Baxter & E. Karamousouli. (2023) Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. ESMO Open 8:4, pages 101593.
Crossref
Crossref
Goran Bencina, Elina Petrova, Demet Sönmez, Sonia Matos Pereira, Ioannis Dimitriadis & Stina Salomonsson. (2023) HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review. Journal of Health Economics and Outcomes Research 10:1.
Crossref
Crossref
H.C. Post, T. Schutte, M.G.H. van Oijen, H.W.M. van Laarhoven & C.E.M. Hollak. (2023) Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries. ESMO Open 8:2, pages 101208.
Crossref
Crossref
P. Nieto-Gómez, C. Castaño-Amores, A. Rodríguez-Delgado & R. Álvarez-Sánchez. (2023) Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement. The European Journal of Health Economics.
Crossref
Crossref
Osnat Bashkin, Keren Dopelt & Noam Asna. (2022) Patients’ and oncologists’ perceptions towards the discussion on high-cost innovative cancer therapies: findings from a qualitative study. BMJ Open 12:9, pages e062104.
Crossref
Crossref
Dario Trapani, Kiu Tay-Teo, Megan E. Tesch, Felipe Roitberg, Manju Sengar, Sara C. Altuna, Michael J. Hassett, Armando A. Genazzani, Aaron S. Kesselheim & Giuseppe Curigliano. (2022) Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Current Oncology 29:8, pages 5774-5791.
Crossref
Crossref
Sasha Thomson, Noah Witzke, Bishal Gyawali, Seanthel Delos Santos, Suji Udayakumar, Claudia Cardone, Matthew C. Cheung & Kelvin K.W. Chan. (2021) Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. European Journal of Cancer 150, pages 203-210.
Crossref
Crossref
Nicole Grössmann, Martin Robausch, Wolfgang Willenbacher, Sarah Wolf, Judit Simon & Claudia Wild. (2020) “Magnitude of clinical benefit” of solid tumour drugs and their real-world application in the Austrian health care setting. Journal of Cancer Policy 25, pages 100235.
Crossref
Crossref
John G. Gribben, Elisabeth de Vries, Nathan I. Cherny & Pieter Sonneveld. (2020) Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?. HemaSphere 4:2, pages e354.
Crossref
Crossref
Tanja Cufer, Tudor E. Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopovic, Jacek Jassem, Dragana Jovanovic, Zhasmina Mihaylova, Gyula Ostoros, Christiane ThallingerMilada Zemanova & Christoph Zielinski. (2020) Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. The Oncologist 25:3, pages e598-e601.
Crossref
Crossref
Barbara Kiesewetter, Nathan I. Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G.E. de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Mría-Victoria. Mateos, Gert J. Ossenkoppele, Kimmo Porkka, Markus Raderer, Josep-Maria Ribera, Lydia Scarfò, Ruth Wester, Panagiota Zygoura & Pieter Sonneveld. (2020) EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open 5:1, pages e000611.
Crossref
Crossref
Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Elizabeth Garrett-Mayer, Shannon E. McKernin, Martine Piccart, Nicola J. Latino, Jean-Yves Douillard, Lowell E. Schnipper, Mark R. Somerfield, Jan Bogaerts, Dimitris Karlis, Panagiota Zygoura, Katerina Vervita, George Pentheroudakis, Josep Tabernero, Christoph Zielinski, Dana S. Wollins & Richard L. Schilsky. (2019) Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology 37:4, pages 336-349.
Crossref
Crossref
Dario Trapani, Giuseppe Curigliano & Alexandru Eniu. (2019) Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. Breast Care 14:6, pages 373-381.
Crossref
Crossref
Ariadna Tibau, Consolación Molto & Eitan Amir. (2018) Response. JNCI: Journal of the National Cancer Institute 110:10, pages 1145-1145.
Crossref
Crossref
Nathan I Cherny, Urani Dafni, Jan Bogaerts, Nicola J Latino, George Pentheroudakis, Jean-Yves Douillard, Josep Tabernero, Christoph Zielinski, Martine J Piccart & Elisabeth G E de Vries. (2018) RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. JNCI: Journal of the National Cancer Institute 110:10, pages 1142-1143.
Crossref
Crossref
Livio Garattini & Anna Padula. (2017) Immunotherapies for advanced melanoma: as promising as they are expensive?. Journal of the Royal Society of Medicine 110:10, pages 395-399.
Crossref
Crossref